Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00251797 · ClinicalTrials.gov registry record · Phase 1
A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors
A Phase 1 study of Cancer and Brain and Nervous System, sponsored by University of New Mexi.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT00251797: Completed Phase 1 study of Cancer and Brain and Nervous System, sponsored by University of New Mexi.
NCT00251797 is a Phase 1 study of Cancer and Brain and Nervous System that has completed, run by University of New Mexi. The registered enrollment target is 10 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00251797, a Phase 1 study of Cancer and Brain and Nervous System, has completed, sponsored by University of New Mexi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will try to answer these questions: 1. What is the highest dose of thalidomide brain cancer patients can receive safely in combination with irinotecan? 2. How well does this combination work to shrink brain tumors, and how long do responses to treatment last? 3. What side effects does the combination of drugs cause? 4. How does treatment affect patients' quality of life (how they feel and what activities they are able to do)?
Conditions Studied
Interventions
- DRUG Irinotecan
- DRUG Thalidomide
Study Locations (1)
New Mexico
- University of New Mexico - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2000-03 |
| Est. Completion | 2006-06 |
| Phase | Phase 1 |
What the finished NCT00251797 record still lists
NCT00251797 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Irinotecan is the first listed.
NCT00251797 reports a single indexed study location in New Mexico.
Frequently Asked Questions
What is clinical trial NCT00251797 about?
NCT00251797 is a clinical study titled "A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors". The study will try to answer these questions: 1. What is the highest dose of thalidomide brain cancer patients can receive safely in combination with irinotecan? 2. How well does this combination work to shrink brain tumors, and how long do responses to treatment last? 3. What side effects does the...
What is the current status of trial NCT00251797?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2000-03. Estimated completion is 2006-06.
What conditions does trial NCT00251797 study?
This clinical trial studies the following conditions: Cancer, Brain and Nervous System.
What interventions are being tested in trial NCT00251797?
The interventions under investigation include: Irinotecan (DRUG), Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00251797?
This trial is sponsored by University of New Mexi, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00251797 being conducted?
This trial has 1 study location across New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00251797's enrollment target sits among peer trials
10 601st of 615 higher than 10 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia